NTRK CONNECT has summarised highlights of the recent ESMO 2019 meeting for you

Dept. of Medical Sciences - University of Turin Pathology Unit, FPO-IRCCS Candiolo Cancer Institute, strada provinciale 142, 10060 Candiolo Caterina Marchiò, MD PhD, obtained her medical degree at The University of Turin graduating summa cum laude in 2004. She completed her PhD in 2008 after working in collaboration between the University of Turin and the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research in London between 2006 and 2008. Upon completion of the residency in Pathology at the University of Turin she visited as a Research Scholar the Department of Pathology at Memorial Sloan Kettering Cancer Centre in New York in 2014. She joined the faculty at the University of Turin as an Assistant Professor of pathology at the end of 2014 and she was appointed Associate Professor of Pathology in 2018. Between 2017 and 2018 she served as Visiting Professor at the Pathology Department of Institut Curie in Paris, as a Mayent-Rotschild grantee. Prof. Caterina Marchiò is a diagnostic and experimental pathologist at the Pathology Unit of FPO-IRCCS Candiolo Cancer Institute (University of Turin). Her routine diagnostic activity focuses on breast pathology and molecular diagnostics of solid tumors, including sign-out for in situ hybridization, DNA sequencing and RNA-based assays applied to diagnostics. Her research interests span from histopathogenesis of breast carcinomas to molecular pathology of special histologic types of breast cancer and genetics of HER2-positive carcinomas. A specific interest in HER2-equivocal breast cancer has been funded by the Italian Association of Cancer Research (AIRC), Regione Piemonte and the Ministry of University, Education and Research. She has also actively worked on the standardization of the preanalytical conditions in Pathology to ensure optimal tissue preservation and quality of DNA, RNA and antigens. She is part of the SPIDIA4P consortium, funded by the European Community (H2020-SC1-2016-2017, EU project 733112 – “SPIDIA4P - SPIDIA for Personalized Medicine).

Assoc. Prof. Caterina Marchiò has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astrazeneca, Bayer, Roche and Daiichi Sankyo. 

Experts
Prof. Viktor Grünwald
  • download Downloadable
    Resouces
  • clock 5 MIN
  • calendar Sep 2021
This educational programme is supported by an Independent Medical Education Grant from Bayer
Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Amoy Diagnostics and Bayer.

Meet the experts

Other programmes of interest

video Video
Oncology 
ER+ metastatic breast cancer: Elacestrant and beyond

Follow a patient's journey during and post-elacestrant treatment for ER+/HER2- metastatic breast cancer

Experts
Prof. Maria Vittoria Dieci
Endorsed by
GRASP
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2024

Educational programme supported by an independent medical education grant from Menarini Stemline Oncology.
podcast Podcast

Episode

3

of 3

episode
Oncology 
Ovarian Cancer: Pre-analytical phase challenges and biomarker testing

Experts
Assoc. Prof. Martina Murphy, Assoc. Prof. Caterina Marchiò, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 32 MIN
  • calendar Feb 2024

Educational programme supported by an independent medical education grant from AstraZeneca and Amoy Diagnostics.
micro-learning Micro learning

Module

2

of 2

module
Oncology 
PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 2 - Evolving landscape of PARPi in mCRPC: Combination with anti-androgens

Experts
Assoc. Prof. Alicia Morgans, Dr Pasquale Rescigno
Endorsed by
ZERO EAUN
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from AstraZeneca
micro-learning Micro learning

Module

1

of 2

module
Oncology 
PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 1 - PARP inhibitors in advanced prostate cancer

Experts
Assoc. Prof. Alicia Morgans, Dr Pasquale Rescigno
Endorsed by
ZERO EAUN
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from AstraZeneca
interactive-patient-case Interactive patient case

Episode

2

of 2

episode
Oncology 
Advanced HCC: Treatment options for patients ineligible for IO

Explore treatment options, adverse event management and next steps in this interactive patient case

Experts
Prof. Sammy Saab
Endorsed by
Blue Faery Digestive Cancers Europe 5th anniversary
Global Liver Institute
  • clock 15 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from Bayer.
podcast Podcast

Episode

2

of 3

episode
Oncology 
Lung Cancer: Pre-analytical phase challenges and biomarker testing

Moderated by the Oncology Brothers. Episode 2 of a 3-part video podcast series

Experts
Dr Bruna Pellini, Dr Semir Vranić, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from AstraZeneca and Amoy Diagnostics.